AR097619A1 - Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris - Google Patents

Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris

Info

Publication number
AR097619A1
AR097619A1 ARP140103378A ARP140103378A AR097619A1 AR 097619 A1 AR097619 A1 AR 097619A1 AR P140103378 A ARP140103378 A AR P140103378A AR P140103378 A ARP140103378 A AR P140103378A AR 097619 A1 AR097619 A1 AR 097619A1
Authority
AR
Argentina
Prior art keywords
acné
acetil
vulgaris
treat
coa carboxylase
Prior art date
Application number
ARP140103378A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR097619A1 publication Critical patent/AR097619A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Reivindicación 1: El uso de un inhibidor ACC, o una sal farmacéuticamente aceptable del mismo, por la elaboración de un medicamento para el tratamiento de acné. Reivindicación 2: El uso de una composición farmacéutica que comprende un inhibidor ACC o una sal farmacéuticamente aceptable del mismo, y al menos un portador farmacéuticamente aceptable del mismo en la elaboración de un medicamento para el tratamiento de acné. Reivindicación 5: El uso de 1-(2-aminoquinolin-7-carbonil)-1-isopropil-4,6-dihidroespiro[indazol-5,4-piperidin]-7(1H)-ona, o una sal farmacéuticamente aceptable del mismo, en la elaboración de un medicamento para el tratamiento de acné.
ARP140103378A 2013-09-12 2014-09-10 Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris AR097619A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361877058P 2013-09-12 2013-09-12

Publications (1)

Publication Number Publication Date
AR097619A1 true AR097619A1 (es) 2016-04-06

Family

ID=51541122

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140103378A AR097619A1 (es) 2013-09-12 2014-09-10 Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris

Country Status (17)

Country Link
US (1) US20160220557A1 (es)
EP (1) EP3043800A1 (es)
JP (1) JP2016534091A (es)
KR (1) KR20160042089A (es)
CN (1) CN105530940A (es)
AR (1) AR097619A1 (es)
AU (1) AU2014319990A1 (es)
BR (1) BR112016004118A2 (es)
CA (1) CA2923884A1 (es)
HK (1) HK1217448A1 (es)
IL (1) IL243969A0 (es)
MX (1) MX2016002479A (es)
RU (1) RU2016106829A (es)
SG (1) SG11201600711PA (es)
TW (1) TW201521722A (es)
WO (1) WO2015036892A1 (es)
ZA (1) ZA201601084B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017147161A1 (en) * 2016-02-23 2017-08-31 Raju Mohan Treatment of dermatological disorders or conditions
US11541046B2 (en) 2017-06-30 2023-01-03 Quixgen, Inc. Spirolactone compounds
WO2019072478A1 (en) 2017-10-10 2019-04-18 Galderma Research & Development SPECIFIC ACETYL-COA CARBOXYLASE INHIBITORS FOR USE IN THE TREATMENT AND / OR PREVENTION OF ACNE
TW201930265A (zh) 2017-12-11 2019-08-01 西班牙商阿爾米雷爾有限公司 作為acc抑制劑的吡咯衍生物
GB201812561D0 (en) * 2018-08-01 2018-09-12 Univ Manchester Biomarkers and uses thereof
WO2020245291A1 (en) 2019-06-06 2020-12-10 Almirall, S.A. Pyrrole derivatives as acc inhibitors
WO2020245297A1 (en) 2019-06-06 2020-12-10 Almirall, S.A. Pyrrole derivatives as acc inhibitors
CN111574530B (zh) * 2020-04-21 2022-07-26 徐州医科大学 一种acc抑制剂及其医药用途
EP4014964A1 (en) 2020-12-21 2022-06-22 Almirall S.A. Topical formulation
US20240109915A1 (en) * 2022-07-29 2024-04-04 Pfizer Inc. Novel acc inhibitors

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5855897A (en) * 1996-09-13 1999-01-05 E-L Management Corp. Topical composition and method for enhancing lipid barrier synthesis
JPH11171848A (ja) 1997-09-26 1999-06-29 Fujirebio Inc 芳香族アミド誘導体
JPH11171847A (ja) 1997-09-26 1999-06-29 Fujirebio Inc ブタン酸アミド誘導体
US6120756A (en) * 1998-08-19 2000-09-19 Philip I. Markowitz Topical anionic salicylate for disorders of the skin
JP2003516938A (ja) 1999-11-12 2003-05-20 ザ ジョンズ ホプキンス ユニバーシティー スクール オブ メディシン 細胞補酵素ａレベルの低下によって癌細胞を選択的に死滅させる方法
PT1423381E (pt) * 2001-09-06 2007-04-30 Schering Corp Inibidores de 17-b-hidroxiesteróide-desidrogenase do tipo 3 para o tratamento de doenças dependentes de androgénio
JP2005194191A (ja) 2001-12-28 2005-07-21 Ajinomoto Co Inc 抗肥満薬、脂肪肝治療薬
JP2005162612A (ja) 2002-01-09 2005-06-23 Ajinomoto Co Inc アシルスルホンアミド誘導体
IL163659A0 (en) 2002-02-27 2005-12-18 Pfizer Prod Inc Acc inhibitors
US6485941B1 (en) 2002-04-23 2002-11-26 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Inhibition of the carboxyltransferase component of acetyl-CoA carboxylase, and the use of such inhibition in anti-cancer and anti-lipogenic therapies
US7211423B2 (en) 2004-07-23 2007-05-01 Bristol-Myers Squibb Co. Acetyl CoA carboxylase 2 sequences and methods
WO2006017494A2 (en) 2004-08-02 2006-02-16 Elizabeth Mazzio Inhibition of anaerobic glucose metabolism
US20060178400A1 (en) 2004-11-05 2006-08-10 Beutel Bruce A Novel acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome
AU2006235451A1 (en) 2005-04-08 2006-10-19 Isis Pharmaceuticals, Inc. Compositions and their uses directed to acetyl-CoA carboxylases
US20100160255A1 (en) 2005-07-29 2010-06-24 Takeda Pharmaceutical Company Limited Spiro-cyclic compound
JP2007161630A (ja) * 2005-12-13 2007-06-28 Adeka Corp 皮脂抑制剤
CN101484433A (zh) 2006-02-15 2009-07-15 艾博特公司 新的乙酰辅酶a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合征中的应用
JP2009526868A (ja) 2006-02-15 2009-07-23 アボット・ラボラトリーズ 新規なアセチル−ＣｏＡカルボキシラーゼ（ＡＣＣ）阻害薬およびこれらの糖尿病、肥満および代謝症候群における使用
EP1996567B1 (en) 2006-02-15 2013-09-18 AbbVie Inc. Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
US20090281097A1 (en) 2006-04-14 2009-11-12 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound
US20100204317A1 (en) * 2006-11-03 2010-08-12 Qlt Inc. Methods of treating dermatological disorders or conditions
KR20080052024A (ko) 2006-12-07 2008-06-11 (주)아모레퍼시픽 아세틸-조효소 ａ 카복실라제 저해활성을 갖는트리아졸로피리다진 유도체
WO2008072850A1 (en) 2006-12-11 2008-06-19 Amorepacific Corporation Triazine derivatives having inhibitory activity against acetyl-coa carboxylase
US7928243B2 (en) 2006-12-21 2011-04-19 Abbott Laboratories Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome
JP2008179621A (ja) 2006-12-28 2008-08-07 Taisho Pharmaceutical Co Ltd 含窒素飽和複素環化合物
PE20081559A1 (es) 2007-01-12 2008-11-20 Merck & Co Inc DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA
WO2008090944A1 (ja) 2007-01-25 2008-07-31 Takeda Pharmaceutical Company Limited スピロ環化合物
US20100113418A1 (en) 2007-02-20 2010-05-06 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2008121592A2 (en) 2007-03-30 2008-10-09 Takeda Pharmaceutical Company Limited Acetyl coenzyme a carboxylase inhibitors
WO2008140828A1 (en) 2007-05-14 2008-11-20 Accera, Inc. Inhibitors of acetyl-coa carboxylase for treatment of neuronal hypometabolism
AU2008287542C1 (en) 2007-06-01 2015-01-22 The Trustees Of Princeton University Treatment of viral infections by modulation of host cell metabolic pathways
WO2009055682A1 (en) 2007-10-26 2009-04-30 Janssen Pharmaceutica N.V. Crystal structure of the carboxyl transferase domain of human acetyl-coa carboxylase 2 protein (acc2 ct) and uses thereof
JP2009196966A (ja) 2008-02-25 2009-09-03 Takeda Chem Ind Ltd ピラゾリジンジオン誘導体
US7981904B2 (en) 2008-03-20 2011-07-19 Takeda Pharmaceutical Company Limited Acetyl CoA carboxylase inhibitors
CA2724774C (en) 2008-05-28 2013-06-25 Pfizer Inc. Pyrazolospiroketone acetyl-coa carboxylase inhibitors
JP2011521940A (ja) 2008-05-28 2011-07-28 ファイザー・インク ピラゾロスピロケトンアセチルＣｏＡカルボキシラーゼ阻害剤
CA2729412A1 (en) 2008-07-04 2010-01-07 Banyu Pharmaceutical Co., Ltd. Novel spirochromanone carboxylic acids
JP2010043019A (ja) 2008-08-12 2010-02-25 Taisho Pharmaceutical Co Ltd ピペリジニルピペラジン化合物
US8501804B2 (en) 2008-10-27 2013-08-06 Takeda Pharmaceutical Company Limited Bicyclic compound
US20100113473A1 (en) 2008-10-30 2010-05-06 Player Mark R Aryl amide compound as an acetyl coenzyme a carboxylase inhibitor
US20100280067A1 (en) * 2009-04-30 2010-11-04 Pakala Kumara Savithru Sarma Inhibitors of acetyl-coa carboxylase
WO2010127208A1 (en) 2009-04-30 2010-11-04 Forest Laboratories Holdings Limited Inhibitors of acetyl-coa carboxylase
WO2011005660A1 (en) 2009-07-08 2011-01-13 Valocor Therapeutics, Inc. Tofa analogs useful in treating dermatological disorders or conditions
DK2499139T3 (da) 2009-11-10 2014-01-27 Pfizer N1-pyrazolospiroketon-acetyl-coa-carboxylasehæmmere
CN101876925B (zh) 2009-11-27 2012-05-02 成都市华为赛门铁克科技有限公司 内存镜像处理方法、装置和***
US8394858B2 (en) 2009-12-03 2013-03-12 Novartis Ag Cyclohexane derivatives and uses thereof
DE102010008642A1 (de) 2010-02-15 2011-08-18 Bayer Schering Pharma Aktiengesellschaft, 13353 Zyklische Ketoenole zur Therapie
DE102010008643A1 (de) 2010-02-15 2011-08-18 Bayer Schering Pharma Aktiengesellschaft, 13353 Zyklische Ketoenole zur Therapie
DE102010008644A1 (de) 2010-02-15 2011-08-18 Bayer Schering Pharma Aktiengesellschaft, 13353 Zyklische Ketoenole zur Therapie
JP2011225455A (ja) 2010-04-15 2011-11-10 Kao Corp Ｓｒｅｂｐ抑制剤
MA34245B1 (fr) 2010-04-27 2013-05-02 Takeda Pharmaceutcal Company Ltd Dérivés de composés bicycliques et leur utilisation en tant qu'inhibiteurs de l'acc.
US9006450B2 (en) 2010-07-01 2015-04-14 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
US8697739B2 (en) 2010-07-29 2014-04-15 Novartis Ag Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
US20120129833A1 (en) 2010-08-20 2012-05-24 Bayer Pharma Aktiengesellschaft Cyclic ketoenols for therapy
US8835472B2 (en) 2010-09-02 2014-09-16 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
US8877754B2 (en) 2010-09-06 2014-11-04 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
HUE025078T2 (en) 2010-10-29 2016-01-28 Pfizer N1 / N2-lactam-acetyl-CoA carboxylase inhibitors
JP5824517B2 (ja) 2010-11-30 2015-11-25 武田薬品工業株式会社 二環性化合物
WO2012090219A2 (en) 2010-12-31 2012-07-05 Jubilant Biosys Ltd. Thiazole compounds useful as acetyl-coa carboxylase (acc) inhibitors
EP2670408A1 (de) 2011-02-06 2013-12-11 Bayer Intellectual Property GmbH (5s,8s)-3-(4'-chlor-3'-fluor-4-methylbiphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-on (verbindung a) zur therapie
WO2012108478A1 (ja) 2011-02-09 2012-08-16 武田薬品工業株式会社 単環化合物
HUE028602T2 (hu) * 2011-04-22 2016-12-28 Pfizer Pirazolospiroketon-származékok acetil-CoA-karboxiláz inhibitorokként történõ alkalmazásra
DE102011080406A1 (de) 2011-08-04 2013-02-07 Bayer Pharma AG Substituierte 3-(Biphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro8[4.5]dec-3-en-2-one
US8844103B2 (en) 2011-09-01 2014-09-30 Medtronic, Inc. Methods for making feedthrough assemblies including a capacitive filter array
US20150246938A1 (en) 2011-09-09 2015-09-03 Shionogi & Co., Ltd. Novel olefin derivative
CN103998432A (zh) 2011-10-24 2014-08-20 武田药品工业株式会社 双环化合物
JP6114297B2 (ja) 2011-11-11 2017-04-12 ギリアド アポロ， エルエルシー Ａｃｃ阻害剤およびその使用
WO2013079668A1 (en) 2011-12-02 2013-06-06 Boehringer Ingelheim International Gmbh Piperidine derivatives, pharmaceutical compositions and uses thereof
US8765959B2 (en) 2011-12-23 2014-07-01 Boehringer Ingelheim International Gmbh Piperidine derivatives
US8530461B2 (en) 2011-12-29 2013-09-10 Boehringer Ingelheim International Gmbh Azetidine derivatives
US8623860B2 (en) 2011-12-30 2014-01-07 Boehringer Ingelheim International Gmbh Azetidine derivatives, pharmaceutical compositions and uses thereof

Also Published As

Publication number Publication date
CA2923884A1 (en) 2015-03-19
SG11201600711PA (en) 2016-03-30
EP3043800A1 (en) 2016-07-20
ZA201601084B (en) 2017-05-31
AU2014319990A1 (en) 2016-02-25
US20160220557A1 (en) 2016-08-04
TW201521722A (zh) 2015-06-16
HK1217448A1 (zh) 2017-01-13
CN105530940A (zh) 2016-04-27
IL243969A0 (en) 2016-04-21
KR20160042089A (ko) 2016-04-18
MX2016002479A (es) 2016-05-31
JP2016534091A (ja) 2016-11-04
BR112016004118A2 (pt) 2017-10-17
RU2016106829A (ru) 2017-10-17
WO2015036892A1 (en) 2015-03-19

Similar Documents

Publication Publication Date Title
AR097619A1 (es) Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
BR112015020466A8 (pt) inibidores de cdc7, seus usos, e composição farmacêutica
CL2018000706A1 (es) Derivados de pirazolopirimidina como inhibidores btk para el tratamiento del cancer.
NI201600058A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4
CL2016001604A1 (es) “compuestos derivados de pirazolo[1,5-a]piridina, inhibidores de quinasas axl y c-met; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
BR112015026006A2 (pt) métodos para o tratamento de câncer com o uso de terapia de combinação com inibidor de cinase tor
UY35907A (es) Nuevas indazolcarboxamidas, procedimientos para su preparación, preparaciones farmaceuticas que las contienen, así como su uso para la preparación de medicamentos
BR112016024545A2 (pt) derivados de pirazolo pirimidina e seu uso como inibidores de malt1
GT201500053A (es) Composicion farmaceutica recubierta que contiene regorafenib
PH12016502355A1 (en) Pharmaceutical composition
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
WO2015054619A3 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
WO2014145642A3 (en) Nrf2 small molecule inhibitors for cancer therapy
NI201400111A (es) Tratamiento del cáncer con inhibidores tor cinasa
AR103680A1 (es) Inhibidores selectivos de bace1
AR087107A1 (es) Compuesto inhibidor de la señalizacion de la trayectoria notch
GT201400059A (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, proceidmientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparacion de medicamentos
CL2015000039A1 (es) Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis.
NI201800071A (es) Compuestos de isoindol
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
CL2015002847A1 (es) Sistemas y métodos para tratar una respuesta farmacodinámica adversa inducida por opioides (divisional de la solicitud n° 0110-2015).
BR112016005317A2 (pt) derivados de quinazolina e seu uso como inibidores de dna metiltransferase
BR112017004580A2 (pt) composto, composição farmacêutica, produto de combinação, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento.

Legal Events

Date Code Title Description
FB Suspension of granting procedure